NCT03075527 2026-01-08A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural MesotheliomaDana-Farber Cancer InstitutePhase 2 Terminated19 enrolled 12 charts
NCT05380713 2025-12-29......SMARTEST Trial......University Health Network, TorontoPhase 2 Completed30 enrolled